


Appendix A

Claim Amendments

1. (Currently amended) ~~Compounds~~ A compound of formula I



(I)

in which

- R1 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
R2 is hydrogen or 1-4C-alkyl,  
R3 is hydrogen or 1-4C-alkyl,  
R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
R5 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
R6 is -T1-Q1, in which  
T1 is a bond, or 1-4C-alkylene,  
Q1 is Ar1, Aa1, Hh1, or Ah1, in which  
Ar1 is phenyl, or R61- and/or R62-substituted phenyl, in  
which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond, and

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen; or 1-4C-alkyl,

R6112 is 1-4C-alkyl, and

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, or 4N-(1-4C-alkyl)-piperazino,

or

T2 is 1-4C-alkylene, or 2-4C-alkylene interrupted by oxygen, and

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen, or 1-4C-alkyl,

R6112 is 1-4C-alkyl, and

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, 4N-(1-4C-alkyl)-piperazino, imidazolo, pyrrolo or pyrazolo,

R62 is 1-4C-alkyl, 1-4C-alkoxy, halogen, cyano, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonylamino, or 1-4C-alkylsulphonylamino,

Aa1 is a bisaryl radical made up of two aryl groups, which are independently selected ~~independently from a~~ from the group consisting of phenyl and naphthyl, and which are linked together via a single bond,


Hh1 is a bisheteroaryl radical made up of two heteroaryl groups, which are independently selected ~~independently from a~~ from the group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and which are linked together via a single bond,

Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected from the **[[a]]** group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from the **[[a]]** group consisting of

phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond,

R7 is hydroxyl, or Cyc1, in which

Cyc1 is a ring system of formula Ia



in which

A is C (carbon),

B is C (carbon),

R71 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,

R72 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,

M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which

Ar2 is a benzene ring,

Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur,

or a salt thereof

~~and the salts of these compounds.~~

2. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1.

in which

R1 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R2 is hydrogen or 1-4C-alkyl,

R3 is hydrogen or 1-4C-alkyl,

R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R5 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R6 is -T1-Q1, in which

T1 is a bond, or 1-4C-alkylene,

Q1 is Ar1, Aa1, Hh1, or Ah1, in which

Ar1 is phenyl, or R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

T2 is a bond, 1-4C-alkylene, or 2-4C-alkylene interrupted by oxygen,

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the

group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen, or 1-4C-alkyl,

R6112 is 1-4C-alkyl,

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,

R62 is 1-4C-alkyl, 1-4C-alkoxy, halogen, cyano, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonylamino, or 1-4C-alkylsulphonylamino,

Aa1 is a bisaryl radical made up of two aryl groups, which are independently selected ~~independently from a~~ from the group consisting of phenyl and naphthyl, and which are linked together via a single bond,


Hh1 is a bisheteroaryl radical made up of two heteroaryl groups, which are independently selected ~~independently from a~~ from the group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and which are linked together via a single bond,

Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected from the **[[a]]** group consisting of monocyclic 5- or 6-

membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from the **[[a]]** group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond,

R7 is hydroxyl, or Cyc1, in which

Cyc1 is a ring system of formula Ia



in which

A is C (carbon),

B is C (carbon),

R71 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,

R72 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,

M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which

Ar2 is a benzene ring,

Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur,



or a salt thereof

~~and the salts of these compounds.~~

3. (Currently amended) ~~Compounds~~ A compound of formula I  
according to claim 1

in which

R1 is hydrogen, or 1-4C-alkyl,

R2 is hydrogen, or 1-4C-alkyl,

R3 is hydrogen, or 1-4C-alkyl,

R4 is hydrogen, or 1-4C-alkyl,

R5 is hydrogen, or 1-4C-alkyl,

R6 is -T1-Q1, in which

T1 is a bond, or 1-4C-alkylene,

Q1 is Ar1, Aa1, Hh1, or Ah1, in which

Ar1 is phenyl, or R61-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-  
4C-alkyl, in which

Har1 is either

a monocyclic 5-membered unsaturated heteroaromatic  
ring comprising one, two or three heteroatoms, each of

which is selected from the group consisting of nitrogen, oxygen and sulfur, or

a monocyclic 6-membered unsaturated heteroaromatic ring comprising one or two nitrogen atoms, or

a fused bicyclic 9-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or

a fused bicyclic 10-membered unsaturated heteroaromatic ring comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-4C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino,

or

T2 is 1-4C-alkylene,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is either

a monocyclic 5-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or

a monocyclic 6-membered unsaturated heteroaromatic ring comprising one or two nitrogen atoms, or

a fused bicyclic 9-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or

a fused bicyclic 10-membered unsaturated heteroaromatic ring comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-4C-alkyl, or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino,

Aa1 is a biphenyl radical,

Hh1 is a bipyridyl, pyrazolyl-pyridinyl, imidazolyl-pyridinyl, or pyridinyl-thiophenyl radical,

Ah1 is a pyridinyl-phenyl, pyrazolyl-phenyl, or  
imidazolyl-phenyl radical,

R7 is hydroxyl, or 2-aminophenyl,

or a salt thereof

~~and the salts of these compounds.~~

4. (Currently amended) ~~Compounds~~ A compound of formula I  
according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, Aa1, Hh1, or Ah1, in which

T1 is a bond, or 1-2C-alkylene,

Q1 is Ar1, in which

Ar1 is phenyl, or R61-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-  
2C-alkyl, in which

Har1 is pyridinyl, benzimidazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl or indolyl, and  
R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,  
or R611 and R612 together and with inclusion of the  
nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which  
Het1 is morpholino,  
or  
T2 is 1-2C-alkylene,  
R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-  
2C-alkyl, in which  
Har1 is pyridinyl, benzimidazolyl, benzoxazolyl,  
benzofuranyl, benzothiophenyl or indolyl, and  
R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,  
or R611 and R612 together and with inclusion of the  
nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which  
Het1 is morpholino,  
Aa1 is a biphenyl radical,  
Hh1 is a bipyridyl, pyrazolyl-pyridinyl, imidazolyl-  
pyridinyl, or pyridinyl-thiophenyl radical,  
Ah1 is a pyridinyl-phenyl, pyrazolyl-phenyl, or  
imidazolyl-phenyl radical,

R7 is hydroxyl, or 2-aminophenyl,  
or a salt thereof  
~~and the salts of these compounds.~~

5. (Currently amended) ~~Compounds~~ A compound of formula I  
according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which

T1 is a bond,

Q1 is Ar1, in which

Ar1 is phenyl, or R61-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is 1-4C-alkyl, and

R612 is 1-4C-alkyl,

or

T2 is 1-2C-alkylene,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which

Har1 is pyridinyl, or indolyl, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino,

Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,

Hh1 is a pyridinyl-thiophenyl radical,

Ah1 is a 3-(pyridinyl)-phenyl, 3-(pyrazolyl)-phenyl, 4-(pyridinyl)-phenyl or 4-(pyrazolyl)-phenyl radical,

R7 is hydroxyl, or 2-aminophenyl,

or a salt thereof

~~and the salts of these compounds.~~

6. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,  
R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
T1 is a bond,  
Q1 is Ar1, in which  
Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
R61 is methyl, or -T2-N(R611)R612, in which  
either  
T2 is a bond,  
R611 is methyl, and  
R612 is methyl,  
or  
T2 is methylene,  
R611 is hydrogen, methyl, isobutyl, benzyl, Har1-methyl, or  
2-(Har1)-ethyl in which  
Har1 is pyridinyl or indolyl, and  
R612 is hydrogen, methyl, or 2-hydroxy-ethyl,  
or R611 and R612 together and with inclusion of the  
nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which  
Het1 is morpholino,  
Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
Hh1 is a pyridinyl-thiophenyl radical,



Ah1 is a 3-(pyridinyl)-phenyl, 3-(pyrazolyl)-phenyl, 4-(pyridinyl)-phenyl or 4-(pyrazolyl)-phenyl radical,

R7 is hydroxyl, or 2-aminophenyl,

or a salt thereof

~~and the salts of these compounds.~~

7. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which

T1 is a bond,

Q1 is Ar1, in which

Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which

R61 is methyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is methyl, and

R612 is methyl,

or

T2 is methylene,

R611 is hydrogen, methyl, isobutyl, benzyl, Har1-methyl, or  
2-(Har1)-ethyl in which

Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indol-3-yl  
or indol-5-yl, and

R612 is hydrogen, methyl, or 2-hydroxy-ethyl,

or R611 and R612 together and with inclusion of the  
nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which

Het1 is morpholino,

Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,

Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,

Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl,  
3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-phenyl,  
4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-  
(pyrazol-1-yl)-phenyl or 4-(1H-pyrazol-4-yl)-phenyl,

R7 is hydroxyl, or 2-aminophenyl,

or a salt thereof

~~and the salts of these compounds.~~

8. (Currently amended) ~~Compounds~~ A compound of formula I  
according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which

T1 is a bond,

Q1 is Ar1, in which

Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which

R61 is methyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is methyl, and

R612 is methyl,

or

T2 is methylene,

R611 is hydrogen, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl, in which

Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indol-3-yl or indol-5-yl, and

R612 is hydrogen,

or

T2 is methylene,

R611 is methyl, or 2-(Har1)-ethyl, in which

Har1 is indol-2-yl, and

R612 is methyl,

or

T2 is methylene,

R611 is 2-(Har1)-ethyl, in which

Har1 is indol-2-yl, and

R612 is 2-hydroxy-ethyl,

or

T2 is methylene, and

R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino,

Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,

Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,

Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl,  
3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-phenyl,  
4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-  
(pyrazol-1-yl)-phenyl or 4-(1H-pyrazol-4-yl)-phenyl,

R7 is hydroxyl,

or a salt thereof

~~and the salts of these compounds.~~

9. (Currently amended) ~~Compounds~~ A compound of formula I  
according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which

T1 is a bond,

Q1 is Ar1, in which

Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which

R61 is methyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is methyl, and

R612 is methyl,

or

T2 is methylene,

R611 is hydrogen, isobutyl, benzyl, Har1-methyl, or 2-  
(Har1)-ethyl, in which

Har1 is pyridin-3-yl, pyridin-4-yl, indol-3-yl, or indol-5-yl, and

R612 is hydrogen,

or

T2 is methylene,

R611 is methyl, or 2-(Har1)-ethyl, in which

Har1 is indol-2-yl, and

R612 is methyl,

or

T2 is methylene,

R611 is 2-(Har1)-ethyl, in which

Har1 is indol-2-yl, and

R612 is 2-hydroxy-ethyl,

or

T2 is methylene, and

R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino,

Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,

Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,

Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl,  
3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-phenyl,

4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-(pyrazol-1-yl)-phenyl or 4-(1H-pyrazol-4-yl)-phenyl,  
R7 is 2-aminophenyl,  
or a salt thereof  
~~and the salts of these compounds.~~

**10.** (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, or biphenyl, in which

T1 is a bond, or 1-2C-alkylene,

Q1 is Ar1, in which

Ar1 is phenyl, or R61-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

T2 is a bond, or 1-2C-alkylene,

R611 is 1-4C-alkyl, or Har1-1-2C-alkyl, in which

Har1 is benzimidazolyl, or indolyl,

R612 is 1-4C-alkyl,

R7 is hydroxyl, or 2-aminophenyl,  
or a salt thereof  
~~and the salts of these compounds.~~

**11.** (Currently amended) ~~Compounds~~ A compound of formula I  
according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, biphenyl, or benzyl, in which

T1 is a bond,

Q1 is Ar1, in which

Ar1 is R61-substituted phenyl, in which

R61 is methyl, dimethylamino, or -T2-N(R611)R612, in which

T2 is methylene,

R611 is methyl, or 2-(indol-2-yl)ethyl,

R612 is methyl,

R7 is hydroxyl, or 2-aminophenyl,

or a salt thereof

~~and the salts of these compounds.~~



12. (Currently amended) A compound of formula I according to claim 1 which is selected from the group consisting of

1. (E)-N-Hydroxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
2. N-Hydroxy-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide,
3. (E)-3-[1-(Biphenyl-4-sulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
4. (E)-3-[1-(4-Dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
5. (E)-N-(2-Amino-phenyl)-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
6. (E)-N-(2-Amino-phenyl)-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide,
7. (E)-N-(2-Amino-phenyl)-3-[1-(biphenyl-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
8. (E)-N-(2-Amino-phenyl)-3-[1-(4-dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
9. (E)-N-Hydroxy-3-(1-[4-((2-(1H-indol-2-yl)-ethyl)-methyl-amino)-methyl)-benzene sulfonyl]-1H-pyrrol-3-yl)-acrylamide,

10. (E)-3-[1-(4-Dimethylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
11. (E)-N-Hydroxy-3-[1-(4-[(pyridin-3-ylmethyl)-amino]-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
12. (E)-N-Hydroxy-3-[1-(4-[(1H-indol-3-ylmethyl)-amino]-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
13. (E)-3-[1-[4-(Benzylamino-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
14. (E)-N-Hydroxy-3-[1-[4-(isobutylamino-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
15. (E)-N-Hydroxy-3-[1-(4-[(1H-indol-5-ylmethyl)-amino]-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
16. (E)-N-Hydroxy-3-[1-(4-[(pyridin-4-ylmethyl)-amino]-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
17. (E)-3-[1-(4-Aminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
18. (E)-N-Hydroxy-3-[1-(4-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
19. (E)-N-Hydroxy-3-[1-[4-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
20. (E)-N-(2-Amino-phenyl)-3-[1-(4-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,

21. (E)-N-(2-Amino-phenyl)-3-[1-(4-pyridin-3-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
22. (E)-N-(2-Amino-phenyl)-3-{1-[4-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide,
23. (E)-3-[1-(Biphenyl-3-sulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
24. (E)-N-Hydroxy-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
25. (E)-N-Hydroxy-3-[1-(4-pyrazol-1-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
26. (E)-N-(2-Amino-phenyl)-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
27. (E)-N-Hydroxy-3-[1-(4-morpholin-4-ylmethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
28. (E)-N-Hydroxy-3-{1-[4-((2-hydroxy-ethyl)-[2-(1H-indol-2-yl)-ethyl]-amino)-methyl]-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide,
29. (E)-N-Hydroxy-3-[1-(3-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
30. (E)-N-(2-Amino-phenyl)-3-[1-(3-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
31. (E)-N-(2-Amino-phenyl)-3-[1-(3-pyridin-3-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,

32. (E)-N-Hydroxy-3-{1-[3-(1H-pyrazol-4-yl)-  
benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide, [[and]]

33. (E)-N-(2-Amino-phenyl)-3-{1-[3-(1H-pyrazol-4-yl)-  
benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide,

and the salts

~~or a salt~~ thereof.

13. (Canceled)

14. (Currently amended) A pharmaceutical composition comprising one [[on]] or more compounds of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and/or vehicle ~~customary pharmaceutical excipients and/or vehicles.~~

15. - 17. (Canceled)

18. (Currently amended) A method for treating a disease ~~diseases~~ in a patient comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

19. (Currently amended) A method for treating benign and/or malignant neoplasia, ~~such as e.g. cancer,~~ in a patient comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof ~~optionally, simultaneously, sequentially or separately with one or more further therapeutic agents.~~

20. (Currently amended) A method for treating a non-malignant disease ~~diseases, such as e.g. arthropathies and osteopathological conditions, systemic lupus erythematosus, rheumatoid arthritis, smooth muscle cell proliferation including vascular proliferative disorders, atherosclerosis and restenosis, or inflammatory conditions,~~ in a patient comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof ~~optionally, simultaneously, sequentially or separately with one or more further therapeutic agents.~~

**21.** (New) A method for treating a disease responsive or sensitive to inhibition of histone deacetylase activity in a patient comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

**22.** (New) The method according to claim 19, wherein the benign and/or malignant neoplasia is cancer.

**23.** (New) The method according to claim 20, wherein the non-malignant disease is selected from the group consisting of arthropathies, osteopathological conditions, systemic lupus erythematosus, rheumatoid arthritis, smooth muscle cell proliferation, vascular proliferative disorders, atherosclerosis, restenosis and inflammatory conditions.

**24.** (New) The method according to claim 19, wherein the compound of formula 1 is administered simultaneously, sequentially or separately with one or more further therapeutic agents.

**25.** (New) The method according to claim 20, wherein the compound of formula 1 is administered simultaneously, sequentially or separately with one or more further therapeutic agents.